Design, synthesis, and evolution of a novel, selective, and orally bioavailable class of thrombin inhibitors: P1-argininal derivatives incorporating P3-P4 lactam sulfonamide moieties.

作者信息

Semple J E, Rowley D C, Brunck T K, Ha-Uong T, Minami N K, Owens T D, Tamura S Y, Goldman E A, Siev D V, Ardecky R J, Carpenter S H, Ge Y, Richard B M, Nolan T G, Håkanson K, Tulinsky A, Nutt R F, Ripka W C

机构信息

Corvas International, Inc., San Diego, California 92121-1102, USA.

出版信息

J Med Chem. 1996 Nov 8;39(23):4531-6. doi: 10.1021/jm960572n.

DOI:10.1021/jm960572n

PMID:8917639

Abstract

摘要

相似文献

Design, synthesis, and evolution of a novel, selective, and orally bioavailable class of thrombin inhibitors: P1-argininal derivatives incorporating P3-P4 lactam sulfonamide moieties.

J Med Chem. 1996 Nov 8;39(23):4531-6. doi: 10.1021/jm960572n.

Discovery of a novel, selective, and orally bioavailable class of thrombin inhibitors incorporating aminopyridyl moieties at the P1 position.发现一类新型、选择性且口服生物可利用的凝血酶抑制剂，其在P1位含有氨基吡啶基部分。

J Med Chem. 1997 Nov 7;40(23):3726-33. doi: 10.1021/jm970493r.

Structure-based design of novel groups for use in the P1 position of thrombin inhibitor scaffolds. Part 2: N-acetamidoimidazoles.用于凝血酶抑制剂支架P1位置的新型基团的基于结构的设计。第2部分：N-乙酰氨基咪唑。

Bioorg Med Chem Lett. 2008 Mar 15;18(6):2062-6. doi: 10.1016/j.bmcl.2008.01.098. Epub 2008 Jan 30.

Novel, potent non-covalent thrombin inhibitors incorporating p(3)-lactam scaffolds.

Bioorg Med Chem Lett. 2002 Mar 11;12(5):743-8. doi: 10.1016/s0960-894x(02)00010-0.

Discovery and development of the novel potent orally active thrombin inhibitor N-(9-hydroxy-9-fluorenecarboxy)prolyl trans-4-aminocyclohexylmethyl amide (L-372,460): coapplication of structure-based design and rapid multiple analogue synthesis on solid support.新型强效口服活性凝血酶抑制剂N-(9-羟基-9-芴基羧基)脯氨酰反式-4-氨基环己基甲基酰胺（L-372,460）的发现与研发：基于结构的设计与在固体载体上的快速多类似物合成的联合应用

J Med Chem. 1998 Jan 29;41(3):401-6. doi: 10.1021/jm9705014.

Design and synthesis of a series of potent and orally bioavailable noncovalent thrombin inhibitors that utilize nonbasic groups in the P1 position.一系列利用P1位非碱性基团的高效且口服生物可利用的非共价凝血酶抑制剂的设计与合成。

J Med Chem. 1998 Aug 13;41(17):3210-9. doi: 10.1021/jm9801713.

Novel thrombin inhibitors incorporating weakly basic heterobicyclic P1-arginine mimetics: optimization via modification of P1 and P3 moieties.

Bioorg Med Chem Lett. 2004 Jun 21;14(12):3251-6. doi: 10.1016/j.bmcl.2004.03.085.

Orally active thrombin inhibitors. Part 2: optimization of the P2-moiety.口服活性凝血酶抑制剂。第2部分：P2部分的优化。

Bioorg Med Chem Lett. 2006 May 15;16(10):2648-53. doi: 10.1016/j.bmcl.2006.01.046. Epub 2006 Feb 3.

Phenolic P2/P3 core motif as thrombin inhibitors--design, synthesis, and X-ray co-crystal structure.

Bioorg Med Chem Lett. 2006 Feb 15;16(4):1032-6. doi: 10.1016/j.bmcl.2005.10.082. Epub 2005 Nov 15.

Cyanoguanidine-based lactam derivatives as a novel class of orally bioavailable factor Xa inhibitors.基于氰基胍的内酰胺衍生物作为一类新型口服生物可利用的凝血因子Xa抑制剂。

Bioorg Med Chem Lett. 2009 Aug 1;19(15):4034-41. doi: 10.1016/j.bmcl.2009.06.014. Epub 2009 Jun 13.

引用本文的文献

Stereoselective formation of a functionalized dipeptide isostere by zinc carbenoid-mediated chain extension.通过锌卡宾介导的链延长实现功能化二肽电子等排体的立体选择性形成。

J Org Chem. 2009 Jan 16;74(2):645-51. doi: 10.1021/jo801993k.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验